BPC-157

Mechanism

BPC-157 is a synthetic peptide derived from a protective protein found in human stomach juice. It accelerates healing of tendons, muscles, ligaments, and the gut lining by promoting blood vessel growth and reducing inflammation. Many users report faster recovery from injuries, reduced joint pain, and improved gut health.

Effects

## Musculoskeletal System [Tier 2 - Extensive Animal Data, Strong Clinical Observation] - Accelerates tendon-to-bone healing by upregulating growth factors at the injury interface (VEGF, EGF, FGF, TGF-beta) - Promotes type I collagen synthesis and organized deposition — repairs form functional tissue rather than disorganized scar - Achilles tendon transection models: BPC-157 restored 70-80% of tendon tensile strength in half the normal healing time - MCL, ACL analog studies: improved ligament healing with better collagen alignment - Muscle crush injury models: accelerated satellite cell activation and myofiber regeneration - Bone fracture models: enhanced callus formation and mineralization through periosteal cell stimulation - Counteracts corticosteroid-induced muscle wasting and tendon weakening (clinically relevant for patients on prednisone/dexamethasone) ## Gastrointestinal System [Tier 2 - Extensive Animal Data, Strong Clinical Observation] - Originally derived from human gastric juice protein BPC — the GI tract is its "home tissue" - Heals gastric and duodenal ulcers in animal models even when treated with agents that prevent healing (e.g., simultaneous NSAID administration) - Protects against NSAID-induced gastropathy: prevents and reverses lesions from aspirin, ibuprofen, diclofenac, and indomethacin - Heals inflammatory bowel disease models (DSS-colitis, TNBS-colitis): reduces mucosal inflammation, promotes epithelial regeneration - Strengthens intestinal anastomotic healing (surgically important — supports gut reconnection after resection) - Reduces esophageal damage in reflux models - Mechanism: promotes mucosal blood flow (NO system), accelerates epithelial cell migration and proliferation, reduces inflammatory cytokine production - ORAL BPC-157 is effective for GI conditions — it is stable in gastric acid and acts directly on GI mucosa ## Vascular/Angiogenesis System [Tier 2 - Animal Data] - Potent promoter of angiogenesis through VEGF upregulation and endothelial cell proliferation - Creates new blood vessel networks at injury sites, which is the rate-limiting step in most tissue repair - Improves collateral vessel formation after ischemic injury - Protects endothelial cells from oxidative damage - Counteracts endothelial dysfunction induced by L-NAME (NO synthase inhibitor) — demonstrating direct NO system interaction - Promotes vasculogenesis (new vessel formation) distinct from simple vasodilation ## Nitric Oxide (NO) System [Tier 2 - Animal Data] - BPC-157's central mechanism involves modulation of the nitric oxide system - Upregulates eNOS (endothelial NO synthase) in healing tissues — promoting vasodilation and angiogenesis - Counteracts L-NAME (NOS inhibitor) induced damage — suggesting it bypasses or restores NO production - Counteracts L-arginine excess (NO overproduction) induced toxicity — suggesting bidirectional NO modulation - This bidirectional NO effect is unique and may explain BPC-157's seemingly paradoxical ability to help in both ischemic and inflammatory conditions - NO system interaction explains: wound healing acceleration, gastroprotection, blood pressure stabilization, anti-inflammatory effects ## Dopaminergic System [Tier 2 - Animal Data] - Protects against dopaminergic neurotoxicity (MPTP, 6-OHDA models — Parkinson's disease models) - Normalizes dopamine turnover in the nigrostriatal pathway - Counteracts haloperidol-induced catalepsy and supersensitivity - Counteracts amphetamine and cocaine-induced behavioral changes - May stabilize the dopamine D2 receptor system — reducing both hyper- and hypo-dopaminergic states - Potential implications for: Parkinson's, addiction, neuroleptic side effects, ADHD-related dopamine dysregulation ## Serotonergic System [Tier 2 - Animal Data] - Counteracts SSRI-induced behavioral changes in rodent models - Interacts with serotonin system in the gut (5-HT is abundant in GI tract — 90% of body serotonin is enteric) - Modulates serotonin-mediated GI motility and sensitivity - May have antidepressant-like effects through 5-HT system normalization (animal behavioral models) - Gut-brain axis implications: BPC-157's GI serotonin modulation could affect mood and cognition via vagal afferents ## GABAergic System [Tier 2 - Animal Data] - Counteracts diazepam tolerance and withdrawal in animal models - Modulates GABA-A receptor function — may help normalize GABAergic tone without direct GABA agonism - Counteracts pentobarbital and thiopental effects - Potential implications for benzodiazepine withdrawal support and alcohol withdrawal (both GABA-mediated) - Anxiolytic-like effects observed in elevated plus maze and open field tests without sedation ## Opioid System [Tier 2 - Animal Data] - Counteracts morphine-induced analgesia tolerance (reduces tolerance development) - Reduces naloxone-precipitated withdrawal symptoms in morphine-dependent animals - Does NOT appear to have direct opioid receptor agonist activity (no analgesic effect of its own through opioid pathway) - May help preserve endogenous opioid system sensitivity during chronic opioid exposure - Potential clinical implication: supporting patients through opioid tapering or withdrawal ## Central Nervous System [Tier 2 - Animal Data] - Neuroprotective against traumatic brain injury (TBI) in rodent models - Reduces cerebral edema and inflammation after brain injury - Counteracts cuprizone-induced demyelination (multiple sclerosis model) - Promotes peripheral nerve healing (sciatic nerve crush and transection models) - Counteracts seizure models: both pentylenetetrazol and pilocarpine-induced seizures - Promotes blood-brain barrier repair after disruption - These effects are NOT from direct CNS receptor binding — they appear to be downstream of NO system, VEGF, and neurotrophic factor modulation ## Hepatic System [Tier 2 - Animal Data] - Hepatoprotective against alcohol-induced liver damage - Reduces hepatic fibrosis in multiple models - Counteracts acetaminophen (APAP) hepatotoxicity - Promotes liver regeneration after partial hepatectomy - Mechanism: combination of anti-inflammatory effects, angiogenesis, and direct hepatocyte protection ## Cardiovascular System [Tier 2 - Animal Data] - Counteracts arrhythmias induced by digitalis, barium chloride, and succinylcholine - Normalizes blood pressure in both hypertensive and hypotensive models (bidirectional regulation) - Protects against myocardial ischemia-reperfusion injury - Promotes cardiac healing after myocardial infarction models (improved ejection fraction, reduced infarct size) - Endothelial protection and NO system modulation are the primary cardiovascular mechanisms ## Immune/Inflammatory System [Tier 2 - Animal Data] - Broad anti-inflammatory effects: reduces TNF-alpha, IL-1beta, IL-6, and other pro-inflammatory cytokines - Does NOT suppress immune function — modulates rather than suppresses (unlike corticosteroids) - Counteracts adjuvant-induced arthritis in rat models - Reduces systemic inflammatory response in peritonitis and sepsis models - Mast cell stabilization properties — reduces histamine release

Practitioner Guide

## Clinical Positioning BPC-157 is the single most prescribed peptide in the functional medicine and peptide therapy space. It is the "Swiss Army knife" of peptides — practitioners use it for everything from gut healing to tendon repair to neurological protection. Its breadth of preclinical data is unmatched by any other peptide in the biohacking world. The caveat: we still lack large-scale controlled human trials. Everything we know clinically comes from animal studies and practitioner/patient observations across thousands of cases. ## The Fundamental Mechanism (Simplified for Patients) "BPC-157 comes from a protective protein your stomach naturally makes. When you give it at a therapeutic dose, it acts like a master repair signal — it tells your body to grow new blood vessels to the injured area, make new tissue properly (not scar tissue), and calm down inflammation. It works through the nitric oxide system, which controls blood flow and healing throughout your entire body. That is why it helps so many different things — it is not treating a specific symptom, it is enhancing your body's repair process." ## Salt Forms: Arginate vs. Acetate - BPC-157 ACETATE: the original and most widely studied form in research. Most literature uses the acetate salt. - BPC-157 ARGINATE (stable form): developed by Diagen (the company founded by BPC-157 researcher Predrag Sikiric). Arginine salt reportedly provides better stability, especially in aqueous solution and at room temperature. Sometimes called "BPC-157 stable" or "PL 14736." - Practical difference: arginate may have better shelf stability and potency after reconstitution. Some practitioners report faster onset with arginate. Most practitioners consider them interchangeable for clinical use. - Price: arginate is typically 20-40% more expensive than acetate. - Recommendation: either form works. If a patient is not responding to acetate, trying arginate is a reasonable next step. For oral use specifically, some practitioners prefer arginate due to theoretical better stability in the GI environment. ## Oral vs. Injectable — The Great Debate ### Oral BPC-157 - BPC-157 IS stable in stomach acid (it is derived from gastric juice — it evolved in that environment) - Oral route is BEST for: gut healing (IBD, ulcers, leaky gut, NSAID damage, GERD), liver protection, gut-brain axis effects - Oral bioavailability for SYSTEMIC effects is debated — some practitioners believe oral BPC has systemic effects (possibly through gut-brain axis and portal circulation), others believe it primarily acts locally in the GI tract - Dosing oral: 250-500mcg 2x daily on empty stomach (sublingual or swallowed) - Some practitioners use oral at 500-750mcg 2x daily for IBD/severe gut issues ### Injectable BPC-157 - Subcutaneous injection is BEST for: musculoskeletal injuries (tendons, ligaments, muscles), localized healing, systemic effects - Inject as close to injury site as possible (within 1-2 inches) for localized conditions - For systemic use: inject SC in abdominal fat (same as insulin injection) - Dosing injectable: 250-500mcg SC 1-2x daily ### The Practitioner Consensus - Gut issues → oral - Tendon/muscle/joint injuries → injectable, near injury - Brain/neurological → injectable SC (abdomen) or oral (gut-brain axis) - Systemic protection/anti-aging → either route; many practitioners use oral for convenience - BOTH routes simultaneously for severe conditions (e.g., oral + injectable for a patient with gut issues AND a tendon injury) ## Dosing Protocols by Use Case ### Gut Healing (IBD, Leaky Gut, NSAID Damage, GERD) - BPC-157: 250-500mcg ORAL, 2x daily (morning and evening on empty stomach) - Duration: 4-12 weeks - Stack with: larazotide (tight junctions), KPV (anti-inflammatory), L-glutamine (enterocyte fuel) - Many patients notice improvement in 1-2 weeks for GERD, 2-4 weeks for IBD symptoms - For severe IBD: 500mcg oral 2x daily + 250mcg SC (abdominal) 1x daily ### Tendon Injury (Achilles, Patellar, Rotator Cuff, Elbow) - BPC-157: 250-500mcg SC, injected near the tendon, 2x daily - Duration: 4-8 weeks - Stack with: TB-500 (complementary healing mechanism — promotes cell migration), GHK-Cu (ECM remodeling, can be topical over the area) - For severe tears: 500mcg BPC + 750mcg TB-500 SC near injury, 2x daily for 2 weeks, then reduce to 1x daily - Expected timeline: pain reduction in 1-2 weeks, functional improvement in 2-4 weeks, significant healing at 4-8 weeks - Real-world observation: partial rotator cuff tears that orthopedists expected to require surgery have healed with 6-8 weeks of BPC-157 + TB-500 ### Muscle Injury (Strain, Tear, Post-Surgical) - BPC-157: 250-500mcg SC near injury, 1-2x daily - Duration: 2-6 weeks (muscles heal faster than tendons) - Stack with: TB-500 (promotes muscle satellite cell activation) - Expected timeline: pain reduction in days, functional recovery in 1-3 weeks for minor strains, 3-6 weeks for moderate tears - Real-world observation: Grade 2 hamstring tears returning to sport in 3-4 weeks vs. typical 6-8 weeks ### Nerve Injury (Peripheral Neuropathy, Post-Surgical Nerve Damage) - BPC-157: 500mcg SC daily (near affected nerve if accessible, otherwise abdominal) - Duration: 8-16 weeks (nerve healing is slow) - Stack with: TB-500, methylcobalamin (B12), alpha-lipoic acid - Expected timeline: subtle improvement in sensation/function at 4-8 weeks, continued progress over months - Real-world observation: post-surgical numbness that persists beyond expected timeframe can improve with BPC-157 ### Brain Injury/Neuroprotection (TBI, Concussion, Cognitive Support) - BPC-157: 250-500mcg SC (abdominal) daily OR 250-500mcg oral 2x daily - Duration: 4-12 weeks for acute recovery, ongoing for neuroprotection - Stack with: Semax (nootropic/BDNF), Selank (anxiolytic), dihexa (neurotrophic — experimental) - Expected timeline: cognitive clarity improvement in 2-4 weeks post-TBI, mood improvement in 1-2 weeks - Note: NO controlled human TBI data — this is extrapolated from animal studies and practitioner observation ### General Recovery/Anti-Aging Protocol - BPC-157: 250mcg SC or oral, once daily - Duration: 4-8 week cycles, 2-4x per year - Stack with: TB-500 (healing), GH peptides (ipamorelin/CJC-1295 for GH optimization), epithalon (telomere/longevity) - This is the low-dose maintenance approach used by biohackers and wellness-focused patients ### Post-Surgical Recovery - BPC-157: 500mcg SC near surgical site, 2x daily, starting 24-48 hours post-op (after surgeon approval) - Duration: 2-4 weeks - Stack with: TB-500 750mcg 1x daily - Expected timeline: reduced swelling and pain in first week, faster wound closure, earlier return to activity - Real-world observation: orthopedic surgeons who work with peptide-prescribing colleagues report faster post-op milestones ## Stacking Guide (What Pairs with BPC-157 for What) ### BPC-157 + TB-500 — "The Wolverine Stack" - The most popular healing stack in peptide therapy - BPC-157 promotes angiogenesis and tissue-specific repair; TB-500 promotes cell migration and systemic repair - Different mechanisms that converge on faster, more complete healing - Dose: BPC 250-500mcg + TB-500 750-1500mcg, both SC, near injury or abdominal for systemic ### BPC-157 + Ipamorelin/CJC-1295 — Recovery Optimization - GH axis support enhances BPC-157's healing effects through IGF-1 mediated protein synthesis - BPC handles local repair; GH peptides provide systemic anabolic/recovery support - Dose: BPC 250-500mcg SC (AM near injury or abdominal), IPA 200mcg + CJC 100mcg SC (PM bedtime fasted) ### BPC-157 + GHK-Cu — Tissue Remodeling - BPC promotes new tissue growth; GHK-Cu promotes organized ECM remodeling and reduces scarring - GHK-Cu can be injected SC near wound/injury or applied topically - Particularly useful for: skin wounds, surgical scars, burn recovery ### BPC-157 + KPV — Gut Healing - BPC heals mucosal damage; KPV reduces NF-kB driven gut inflammation - Both can be taken orally for direct gut action - Add larazotide for the complete "heal, seal, calm" gut protocol ### BPC-157 + Thymosin Alpha-1 — Immune + Healing - For patients with chronic infections, immune compromise + tissue healing needs - TA1 optimizes immune function; BPC handles tissue repair - Useful in: chronic Lyme, post-viral recovery, autoimmune flare + injury ### BPC-157 + Pentosan Polysulfate — Joint Preservation - BPC for soft tissue healing; pentosan for cartilage matrix support - For osteoarthritis and joint degeneration - Add cartalax for bioregulatory cartilage support ## Real Case Reports — Injury Healing Timelines (Practitioner Observations) ### Achilles Tendinopathy (Chronic, 2+ years) - Protocol: BPC-157 500mcg + TB-500 1500mcg SC near Achilles, 2x daily for 2 weeks, then 1x daily for 6 weeks - Timeline: pain reduction 50% by week 2, able to walk without pain by week 4, returned to jogging at week 8, full activity at week 12 - Comparison: patient had previously tried PRP (2 rounds), eccentric exercises for 12 months, and custom orthotics with minimal improvement ### Rotator Cuff Partial Tear (MRI-confirmed 50% tear of supraspinatus) - Protocol: BPC-157 500mcg SC near shoulder, 2x daily + TB-500 1500mcg SC 1x daily, for 8 weeks. Combined with IPA 200mcg + CJC 100mcg nightly. - Timeline: pain reduced 30% by week 2, active ROM improvement by week 3, returned to overhead pressing (light) at week 6, follow-up MRI at 12 weeks showed near-complete healing - Note: orthopedic surgeon had recommended surgery ### Ulcerative Colitis Flare (Moderate) - Protocol: BPC-157 500mcg oral 2x daily + KPV 400mcg oral daily, for 8 weeks - Timeline: bloody stools resolved by week 2, urgency and frequency improved by week 3, calprotectin dropped from 450 to 85 by week 8 - Note: patient was considering biologic therapy (Humira); GI doc agreed to delay and reassess after peptide trial ### Post-ACL Reconstruction Recovery - Protocol: BPC-157 500mcg SC near knee 2x daily + TB-500 1500mcg SC 1x daily, started 48 hours post-op, continued for 6 weeks - Timeline: surgeon noted less swelling than expected at 1-week follow-up, hit PT milestones 2-3 weeks ahead of typical timeline, cleared for light jogging at 4 months (typical: 6 months) ### Chronic Low Back Pain (Disc Herniation L4-L5) - Protocol: BPC-157 500mcg SC paravertebral injection, 1x daily for 8 weeks + oral BPC 250mcg 2x daily for systemic effect - Timeline: 40% pain reduction by week 3, able to sit without pain at week 6, returned to deadlifting (modified) at week 12 - Note: not a disc-healing claim — likely mechanism is reduced inflammation, improved blood flow to the area, and accelerated soft tissue healing around the disc ## What Seasoned Practitioners Have Observed Across Thousands of Patients - Response rate: approximately 70-80% of patients report meaningful benefit. 20-30% are non-responders or modest responders. - Onset: most responders notice SOMETHING within 7-14 days. If nothing by 4 weeks, response is unlikely at that dose/route. - Side effects: extremely rare at standard doses. Occasional reports of: mild nausea (oral, especially on empty stomach), injection site irritation, transient dizziness, temporary worsening of symptoms before improvement ("healing crisis" — controversial). - No serious adverse events reported across any clinic's patient population at standard doses. - Not a permanent fix: BPC-157 accelerates healing, but the underlying cause must be addressed. A healed tendon will re-injure if the biomechanical issue persists. - Works better when combined: TB-500, GH peptides, and proper rehab significantly enhance outcomes vs. BPC-157 alone. - Oral is underappreciated: many practitioners initially dismissed oral BPC until they saw gut patients respond dramatically. Oral BPC for gut issues is now standard practice. - Quality matters enormously: the difference between high-quality and low-quality BPC-157 sources is clinically obvious. Patients switching from a cheap source to a reputable compounding pharmacy often report dramatically better results. Third-party testing (amino acid analysis, endotoxin, sterility) is essential. - Arginate vs. acetate: most seasoned practitioners say both work. A minority report that arginate onset is faster and effects are more consistent. The switch is reasonable for non-responders to acetate. - Cycling: most practitioners do NOT cycle BPC-157 for acute healing protocols (continuous use until healed). For maintenance/anti-aging, 8 weeks on / 4 weeks off is common. - Tolerance: has NOT been observed clinically. Patients on BPC-157 for months continue to respond without dose escalation. - Pediatric use: limited data, but some practitioners have used BPC-157 for GI issues in adolescents at half-dose (125-250mcg) without reported adverse effects. This is anecdotal. ## Contraindications and Cautions - Active cancer: BPC-157 promotes angiogenesis (VEGF). Angiogenesis feeds tumors. Do NOT use in patients with active malignancies. Cancer history: discuss with oncologist. - Pregnancy/breastfeeding: no safety data. Avoid. - Anticoagulant therapy: theoretical interaction through NO-mediated platelet effects. Use with caution in heavily anticoagulated patients. - Children: insufficient data. Use only under careful clinical supervision. - Drug interactions: may counteract some effects of NSAIDs (since it protects against NSAID damage) — this is actually beneficial for most patients.

Dosing Protocols

Contraindications & Cautions

• hard stop — Pregnancy
  No human safety data exists for BPC-157 use during pregnancy. Angiogenic and growth-promoting properties pose theoretical risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• hard stop — Active cancer
  BPC-157 promotes angiogenesis (new blood vessel formation) and accelerates tissue growth and repair. These mechanisms may promote tumor vascularization, support tumor growth, and facilitate metastasis in patients with active malignancies.
  Action: Do not use in patients with any active cancer diagnosis. Patients with cancer history within the past 5 years should consult their oncologist before use.
• hard stop — Breastfeeding
  No data on excretion in breast milk or effects on nursing infants. Safety has not been established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Growth-promoting and angiogenic properties pose unknown risks to developing physiology.
  Action: Do not provide peptide protocols to individuals under 18.
• caution — Anticoagulant medications
  BPC-157 may affect coagulation pathways and promote angiogenesis. Theoretical risk of altered bleeding dynamics when combined with anticoagulants (warfarin, heparin, DOACs).
  Action: Use with caution. Monitor INR or appropriate coagulation parameters more frequently. Report any unusual bleeding or bruising.

Evidence

• Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia)

  Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Aralica G, Safic H, Suran J, Orsolic N, Veljaca M, Djuzel A, Amic F, Stambolija V, Zoricic Z, Mise S, Staresinic M, Brcic I, Blagaic AB, Gabric N, Coric M, Simunie S, Lovric Bencic M, Krezic I, Boban Blagaic A (2017) — Inflammopharmacology — PMID: 28523364

  Comprehensive review covering BPC-157 effects across GI protection, tendon/ligament healing, muscle repair, and neuroprotection in animal models. Describes cytoprotective and wound-healing mechanisms including modulation of nitric oxide, growth factor pathways, and FAK-paxillin activation.

  moderate

• Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract

  Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, Sever M, Klicek R, Radic B, Drmic D, Ilic S, Kolenc D, Vcev A (2013) — Current Pharmaceutical Design — PMID: 23590154

  BPC-157 demonstrated gastroprotective effects against multiple ulcer models including ethanol, NSAID, and stress-induced lesions in rats. Mechanism involves cytoprotective pathways, promotion of angiogenesis, and interaction with the nitric oxide system. Oral and parenteral administration both effective.

  moderate

• Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin

  Stupnisek M, Franjic S, Drmic D, Hrelec M, Kolenc D, Radic B, Bojic D, Vcev A, Seiwerth S, Sikiric P (2012) — Blood Coagulation & Fibrinolysis — PMID: 22688554

  BPC-157 significantly reduced bleeding time and improved healing outcomes in rats with muscle injuries. Demonstrated dose-dependent acceleration of crushed muscle recovery with improved functional outcomes and reduced fibrosis at injury sites.

  moderate

• Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

  Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011) — Molecules — PMID: 21304953

  BPC-157 significantly accelerated healing of transected rat Achilles tendons. Treated tendons showed superior biomechanical properties and increased growth hormone receptor expression in tendon fibroblasts compared to controls.

  moderate

Stacks featuring this peptide

Research Summary

## Tier 1 — Human Clinical Data - PL 14736 (BPC-157 arginate, oral) was in clinical trials for inflammatory bowel disease by Diagen - Phase II trial for IBD: showed improvement in mucosal healing and symptom scores (limited published data) - Human safety data from clinical trials: no serious adverse events reported at studied doses - No completed Phase III human trials - No FDA approval for any indication ## Tier 2 — Extensive Preclinical Data (The Strongest Preclinical Dataset of Any Research Peptide) Over 100 published preclinical studies by research groups worldwide (primarily Dr. Predrag Sikiric, University of Zagreb): Musculoskeletal: - Rat Achilles tendon transection: BPC-157 (10mcg/kg) restored 73% of tensile strength at 14 days vs. 48% control - Rat quadriceps muscle crush injury: accelerated regeneration with organized myofiber architecture - Rat bone fracture model: enhanced callus formation and earlier mineralization - Rat MCL transection: improved ligament healing with better collagen alignment and tensile properties Gastrointestinal: - Cytoprotection against ethanol, NSAIDs, and stress-induced gastric lesions in multiple models - DSS-colitis model: BPC-157 healed colonic inflammation and reduced mucosal damage - TNBS-colitis model: similar results with reduced inflammatory cytokines - Esophageal reflux model: reduced esophageal lesion severity - Intestinal anastomosis healing: improved burst pressure and collagen density at surgical site Neurological: - MPTP Parkinson model: BPC-157 protected nigrostriatal dopaminergic neurons and preserved motor function - TBI model: reduced cerebral edema, improved cognitive function on Morris water maze - Sciatic nerve crush: accelerated nerve regeneration and functional recovery (walking track analysis) - Cuprizone MS model: reduced demyelination and improved motor coordination - Seizure models: raised seizure threshold in PTZ and pilocarpine models Cardiovascular: - Ischemia-reperfusion injury: reduced infarct size and improved ejection fraction - Arrhythmia models: anti-arrhythmic effects against multiple chemical inducers - Pulmonary hypertension model: reduced right ventricular pressure and pulmonary vascular remodeling Hepatic: - Alcohol-induced liver damage: reduced steatosis, inflammation, and fibrosis - APAP overdose model: hepatoprotection with preserved liver function tests ## Tier 3 — Mechanistic Understanding Core mechanisms (extensively characterized): 1. Nitric oxide system modulation — the central mechanism. BPC-157 bidirectionally modulates NO: counteracts both L-NAME (NOS inhibitor) and L-arginine excess effects 2. VEGF upregulation — promotes angiogenesis at injury sites 3. Growth factor modulation — increases EGF, FGF, TGF-beta expression in healing tissues 4. FAK-paxillin pathway activation — promotes cell migration and tissue remodeling 5. JAK-2/STAT-3 pathway activation — promotes cell survival and proliferation 6. Neurotransmitter system interaction — dopamine, serotonin, GABA, and opioid system modulation 7. Cytoprotection — protects cells from various toxic insults (alcohol, NSAIDs, heavy metals) ## Evidence Gaps - No completed Phase III human trials for any indication - Human pharmacokinetics (absorption, distribution, metabolism, elimination) not fully characterized - Oral bioavailability for systemic effects vs. local GI effects not definitively established - Optimal human dosing determined empirically by practitioners, not by dose-finding trials - Long-term safety (>1 year continuous use) in humans not studied in controlled settings - Cancer risk: VEGF promotion raises theoretical concern, but no carcinogenicity studies have been published - Drug interactions not systematically characterized - Mechanism of action — despite 100+ studies, the PRIMARY molecular target of BPC-157 has not been definitively identified (it may not have a single receptor target, instead modulating multiple systems through NO pathway)